Therefore, although further studies are needed, it is possible to hypothesize that inhibitors of PDH activity and/or of GSH biosynthesis could be used in combination with PLX4032 to overcome drug resistance of BRAF-mutated melanoma patients. The gene discussed is PDP1; the disease is melanoma.